Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib as Maintenance Therapy in IDH1-mutated AML and High-risk MDS (IVORY-MAST)
NCT07607418Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ivosidenib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Ruijin Hospital. Started May 2026; status: recruiting.
02
Drugs
ivosidenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07607418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07607418.